A detailed history of Susquehanna International Group, LLP transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Susquehanna International Group, LLP holds 56,761 shares of FATE stock, worth $94,223. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,761
Previous 53,293 6.51%
Holding current value
$94,223
Previous $174,000 13.79%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.12 - $5.57 $10,820 - $19,316
3,468 Added 6.51%
56,761 $198,000
Q2 2024

Aug 15, 2024

SELL
$3.26 - $7.08 $130,540 - $283,504
-40,043 Reduced 42.9%
53,293 $174,000
Q1 2024

May 07, 2024

SELL
$3.54 - $8.35 $209,472 - $494,094
-59,173 Reduced 38.8%
93,336 $685,000
Q4 2023

Feb 14, 2024

SELL
$1.65 - $3.94 $466,327 - $1.11 Million
-282,623 Reduced 64.95%
152,509 $570,000
Q3 2023

Nov 14, 2023

SELL
$2.02 - $5.04 $101,456 - $253,139
-50,226 Reduced 10.35%
435,132 $922,000
Q2 2023

Aug 11, 2023

SELL
$4.76 - $6.59 $1.84 Million - $2.55 Million
-386,856 Reduced 44.35%
485,358 $2.31 Million
Q1 2023

May 16, 2023

BUY
$4.24 - $11.12 $3.54 Million - $9.29 Million
835,597 Added 2281.99%
872,214 $4.97 Million
Q4 2022

Feb 14, 2023

SELL
$9.86 - $23.83 $883,702 - $2.14 Million
-89,625 Reduced 70.99%
36,617 $369,000
Q3 2022

Nov 14, 2022

BUY
$21.04 - $36.06 $208,085 - $356,633
9,890 Added 8.5%
126,242 $2.83 Million
Q2 2022

Aug 15, 2022

BUY
$17.78 - $42.39 $1.09 Million - $2.61 Million
61,539 Added 112.27%
116,352 $2.88 Million
Q1 2022

May 16, 2022

SELL
$29.67 - $60.28 $1.52 Million - $3.1 Million
-51,390 Reduced 48.39%
54,813 $2.13 Million
Q4 2021

Feb 14, 2022

BUY
$47.84 - $64.34 $956,273 - $1.29 Million
19,989 Added 23.19%
106,203 $6.21 Million
Q3 2021

Nov 15, 2021

BUY
$59.27 - $95.73 $3.15 Million - $5.09 Million
53,206 Added 161.19%
86,214 $5.11 Million
Q2 2021

Aug 11, 2021

SELL
$67.25 - $92.52 $615,270 - $846,465
-9,149 Reduced 21.7%
33,008 $2.87 Million
Q1 2021

May 17, 2021

SELL
$72.16 - $117.4 $2.07 Million - $3.36 Million
-28,622 Reduced 40.44%
42,157 $3.48 Million
Q4 2020

Feb 16, 2021

SELL
$38.09 - $100.95 $2.38 Million - $6.31 Million
-62,505 Reduced 46.9%
70,779 $6.44 Million
Q3 2020

Nov 16, 2020

BUY
$30.41 - $40.5 $669,172 - $891,202
22,005 Added 19.77%
133,284 $5.33 Million
Q2 2020

Aug 14, 2020

BUY
$20.21 - $35.23 $1.54 Million - $2.68 Million
75,969 Added 215.15%
111,279 $3.82 Million
Q1 2020

May 15, 2020

SELL
$17.28 - $31.88 $1.04 Million - $1.92 Million
-60,347 Reduced 63.09%
35,310 $784,000
Q4 2019

Feb 14, 2020

BUY
$13.39 - $20.73 $281,497 - $435,806
21,023 Added 28.17%
95,657 $1.87 Million
Q3 2019

Nov 14, 2019

BUY
$15.47 - $22.5 $326,324 - $474,615
21,094 Added 39.4%
74,634 $1.16 Million
Q2 2019

Aug 16, 2019

BUY
$15.61 - $20.44 $478,368 - $626,383
30,645 Added 133.85%
53,540 $1.09 Million
Q2 2018

Aug 14, 2018

SELL
$9.16 - $13.48 $50,737 - $74,665
-5,539 Reduced 19.48%
22,895 $260,000
Q1 2018

May 15, 2018

SELL
$6.3 - $13.77 $130,410 - $285,039
-20,700 Reduced 42.13%
28,434 $278,000
Q4 2017

Feb 14, 2018

BUY
$3.94 - $6.64 $193,587 - $326,249
49,134
49,134 $300,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $161M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.